Dendreon’s (DNDN) flagship drug Provenge has faced a rocky road, but it continues to fight back and overcome all of the doubters. It is the main reason I believe Dendreon is still a quality investment, but it is not the only reason I would put my money where my mouth is.
Dendreon is focused on something few others are: a cancer therapy that aims to do more good than harm. Unfortunately, common treatments for cancer, such as chemotherapy, come with a boatload of side effects. Do not get me wrong, the treatments are valuable and, in many cases, shrink a tumor and prolong a patient’s life. However, this is accomplished at the cost of destroying healthy cells and creating other problems such as anemia and immunodeficiency problems.
The common “symptoms” of cancer are often caused by the treatment and not the disease, such as the loss of hair and the nausea and exhaustion. Some chemotherapy treatments are even carcinogenic themselves and lead to unhealthy cell growth in other parts of the body. Dendreon’s goal is to create treatments that avoid all of these problems and its first effort in the “healthy” fight against cancer is its drug Provenge.
Provenge focuses on building the body’s immune system to fight cancerous tumors and heal without introducing chemotherapy into the body. It is important for both patients and investors to understand that Provenge is not a cure for cancer, and Dendreon is not claiming that it is.To continue reading, click here.
Incoming search terms: